Compare BKV & TMDX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | BKV | TMDX |
|---|---|---|
| Founded | 2015 | 1998 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Electromedical & Electrotherapeutic Apparatus |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 2.6B |
| IPO Year | 2022 | 2019 |
| Metric | BKV | TMDX |
|---|---|---|
| Price | $22.95 | $87.29 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 9 |
| Target Price | $34.22 | ★ $148.22 |
| AVG Volume (30 Days) | ★ 2.0M | 625.0K |
| Earning Date | 05-07-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 199.00 | ★ 382.18 |
| EPS | ★ 1.11 | 0.61 |
| Revenue | ★ $893,781,000.00 | $605,494,000.00 |
| Revenue This Year | $69.39 | $24.25 |
| Revenue Next Year | $9.45 | $18.75 |
| P/E Ratio | ★ $20.66 | $141.47 |
| Revenue Growth | ★ 47.85 | 37.13 |
| 52 Week Low | $20.08 | $60.11 |
| 52 Week High | $32.81 | $156.00 |
| Indicator | BKV | TMDX |
|---|---|---|
| Relative Strength Index (RSI) | 39.86 | 54.02 |
| Support Level | N/A | $80.29 |
| Resistance Level | $27.55 | $95.18 |
| Average True Range (ATR) | 1.04 | 4.21 |
| MACD | -0.24 | -0.29 |
| Stochastic Oscillator | 13.62 | 80.64 |
BKV Corp is a growth-driven energy company focused on the development of natural gas-producing assets, the ownership and operation of natural gas-fired power generation assets, and selective accretive acquisitions. The company's core businesses are the production of natural gas and the generation of natural gas-fired power from its owned and operated assets, supported by a closed-loop plan, enabled by its upstream, midstream, power, and CCUS businesses.
TransMedics Group Inc is a commercial-stage medical technology company transforming organ transplant therapy for end-stage organ failure patients across multiple disease states. It has developed the Organ Care System (OCS) to comprehensively address the limitations of cold storage. The OCS is a portable organ perfusion, optimization, and monitoring system that utilizes technology to replicate near-physiologic conditions for donor organs outside of the human body. The company has developed and is commercializing a proprietary system to preserve and deliver human organs for transplant in a near-physiologic condition to address the limitations of cold storage organ preservation.